On July 10, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported financial results for Q2 2025 and provides a business update (Press release, Alligator Bioscience, JUL 10, 2025, View Source [SID1234654321]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With key regulatory and manufacturing milestones achieved for mitazalimab and strengthened financials, we remain focused on identifying a strategic partner and initiating Phase 3. During the quarter, we successfully completed GMP manufacturing and received clear regulatory feedback from both the FDA and EMA—confirming dose, trial design and paediatric waiver—further strengthening the program’s foundation. In parallel, new biomarker data presented at ASCO (Free ASCO Whitepaper) reinforced mitazalimab’s clinical potential and relevance for patient stratification. Combined with the proceeds from TO 12, these developments move us into the next exciting stage of mitazalimab’s journey."
Søren Bregenholt, CEO of Alligator Bioscience
BUSINESS UPDATE
Mitazalimab

Completion of GMP manufacturing for mitazalimab to support Phase 3 trial readiness in collaboration with development partner.
Paediatric study waiver granted by the European Medicines Agency, streamlining regulatory path ahead of future MAA submission.
Presentation of biomarker data from the Phase 2 trial OPTIMIZE-1 at ASCO (Free ASCO Whitepaper) 2025, showing mitazalimab-induced immune modulation and identifying biomarkers linked to improved outcomes in metastatic pancreatic cancer.
Confirmation from FDA of 900 ug/kg dose and positive scientific advice from EMA further strengthen mitazalimab’s regulatory foundation ahead of Phase 3.
Company

Annual General Meeting held on 7 May 2025; adoption of updated dividend policy aligned with sharpened strategic focus and potential proceeds from asset monetization.
Execution of 1:1000 reverse share split in April 2025, followed by recalculation of terms for TO 12 and TO 13 warrants.
Successful completion of warrant programme TO 12 in May 2025, with 71% of options exercised and SEK 61 million raised before issue costs and partial repayment of loan.
Adjustment of total number of shares to 34,803,898 following TO 12 warrant exercise and share split.
Initiation of Phase 2 clinical trial with HLX22 in HER2-positive breast cancer by Shanghai Henlius; EU Orphan Drug Designation granted for HLX22 in gastric cancer.
FINANCIAL SUMMARY FOR Q2 2025
The financial summaries for the quarterly periods ending 30 June 2025 and 30 June 2024 are presented below.

All amounts in MSEK,
unless specified April – June
2025 April – June
2024
Net sales - 7.6
Operating profit/loss -22.3 -47.4
Profit/loss for the period -1.7 -49.2
Cash flow for the period 5.1 37.4
Cash and cash equivalents 33.9 77.5
Earnings per share before and after dilution, SEK -0.08 -66.36
FINANCIAL SUMMARY FOR H1 2025
The financial summaries for the half-year periods ending 30 June 2025 and 30 June 2024 are presented below.

All amounts in MSEK,
unless specified January – June
2025 January – June
2024
Net sales - 14.6
Operating profit/loss -66.0 -107.0
Profit/loss for the period -10.0 -112.0
Cash flow for the period -29.6 11.3
Cash and cash equivalents 33.9 77.5
Earnings per share before and after dilution, SEK -0.69 -158.50
The full report is attached as a PDF, and is also available on the company’s website: View Source

Alligator will host a webinar on Thursday, July 10 2025, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the April – June 2025 interim report, which will be followed by a Q&A session.